Alpha Tau Medical (NASDAQ:DRTS) Issues Quarterly Earnings Results, Meets Expectations

Alpha Tau Medical (NASDAQ:DRTS) issued its quarterly earnings results on Wednesday. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13), Zacks reports.

Alpha Tau Medical Price Performance

Shares of NASDAQ:DRTS opened at $2.66 on Thursday. The company has a market cap of $186.00 million, a P/E ratio of -6.19 and a beta of 0.87. Alpha Tau Medical has a 1 year low of $1.75 and a 1 year high of $4.39. The stock’s fifty day moving average price is $3.29 and its 200-day moving average price is $2.78.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Alpha Tau Medical in a report on Friday, November 22nd.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.